Immunogenicity of influenza and HSV-1 mixed antigen ISCOMs in mice

Ghazi, Hani; Ertürk, Murat; Stannard, Linda M.; Faulkner, Meryl; Potter, C. W.; Jennings, R.

doi:10.1007/bf01315412

Cited by 7 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, incorporation of DNA plasmid within the ISCOM matrix elicited potent anti- Haemophilus influenzae cellular and Ab responses in the nasopharynx of nasally immunized animals ( 204 ). Oral administration of ISCOM-based vaccines has been evaluated ( 205 , 206 ); however, it seems that the generation of intestinal IgA responses was limited ( 207 ). Although ISCOMs are self-adjuvanted delivery systems, incorporation of the adjuvant CTA1-DD within the structure allowed to induce robust mucosal IgA production and T cell proliferation, together with systemic responses, after nasal administration ( 208 ).…”

Section: Lipid-based Particles For Mucosal Vaccinationmentioning

confidence: 99%

Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection

Corthésy

Bioley

2018

Front. Immunol.

View full text Add to dashboard Cite

Vaccination is the process of administering immunogenic formulations in order to induce or harness antigen (Ag)-specific antibody and T cell responses in order to protect against infections. Important successes have been obtained in protecting individuals against many deleterious pathological situations after parenteral vaccination. However, one of the major limitations of the current vaccination strategies is the administration route that may not be optimal for the induction of immunity at the site of pathogen entry, i.e., mucosal surfaces. It is now well documented that immune responses along the genital, respiratory, or gastrointestinal tracts have to be elicited locally to ensure efficient trafficking of effector and memory B and T cells to mucosal tissues. Moreover, needle-free mucosal delivery of vaccines is advantageous in terms of safety, compliance, and ease of administration. However, the quest for mucosal vaccines is challenging due to (1) the fact that Ag sampling has to be performed across the epithelium through a relatively limited number of portals of entry; (2) the deleterious acidic and proteolytic environment of the mucosae that affect the stability, integrity, and retention time of the applied Ags; and (3) the tolerogenic environment of mucosae, which requires the addition of adjuvants to elicit efficient effector immune responses. Until now, only few mucosally applicable vaccine formulations have been developed and successfully tested. In animal models and clinical trials, the use of lipidic structures such as liposomes, virosomes, immune stimulating complexes, gas-filled microbubbles and emulsions has proven efficient for the mucosal delivery of associated Ags and the induction of local and systemic immune reponses. Such particles are suitable for mucosal delivery because they protect the associated payload from degradation and deliver concentrated amounts of Ags via specialized sampling cells (microfold cells) within the mucosal epithelium to underlying antigen-presenting cells. The review aims at summarizing recent development in the field of mucosal vaccination using lipid-based particles. The modularity ensured by tailoring the lipidic design and content of particles, and their known safety as already established in humans, make the continuing appraisal of these vaccine candidates a promising development in the field of targeted mucosal vaccination.

show abstract